Small cell lung carcinoma with KIF5B-RET fusion partially responded to the 4^(th)-line therapy with anlotinib:A case report  

作　　者：Rui Zhang Yu-Ting He Yi-Sha Liu Hang Li Feng Zhao 

机构地区：[1]Meat Processing Key Laboratory of Sichuan Province,College of Food and Biological Engineering,Chengdu University,Chengdu 610106,Sichuan Province,China [2]School of Medicine,University of Electronic Science and Technology of China,Chengdu 610072,Sichuan Province,China [3]Department of Pathology,Sichuan Provincial People's Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610072,Sichuan Province,China [4]Department of Radiology,Sichuan Provincial People's Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610072,Sichuan Province,China [5]Department of Oncology,Sichuan Provincial People's Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610072,Sichuan Province,China

出　　处：《World Journal of Clinical Cases》2024年第23期5410-5415,共6页世界临床病例杂志

基　　金：Meat Processing Key Laboratory of Sichuan Province,No.22-R-16.

摘　　要：BACKGROUND Small cell lung cancer(SCLC)exhibits a pronounced tendency for metastasis and relapse,and the acquisition of resistance to chemotherapy and radiotherapy,leading to complexity in treatment outcomes.It is crucial to tackle these challenges by advancing targeted therapeutic approaches in ongoing research endeavors.Variant RET fusions have been reported in several solid tumors,but are rarely reported in SCLC.CASE SUMMARY We present the first case of a KIF5B-RET fusion in a 65-year-old male patient with SCLC.To date,the patient has received the 4th line chemotherapy with anlotinib for one year and has shown a sustained favorable partial response.According to the results of next generation sequencing,this SCLC patient harbors the KIF5BRET fusion,suggesting that RET fusion could serve as a promising molecular target for SCLC treatment.Next-generation sequencing(NGS)plays a critical rolein comprehensively assessing the genotype and phenotype of cancer.CONCLUSION NGS can provide SCLC patients with personalized and targeted therapy options,thereby improving their likelihood of survival.

关 键 词：KIF5B-RET fusion Small cell lung cancer Anlotinib Partial response Next-generation sequencing Case report 

分 类 号：R735.2[医药卫生—肿瘤] R459.7[医药卫生—临床医学]